Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility : a Single-Institution Experience by A. Sartore-Bianchi et al.
ORIGINAL RESEARCH ARTICLE
Pooled Analysis of Clinical Outcome of Patients
with Chemorefractory Metastatic Colorectal Cancer Treated
within Phase I/II Clinical Studies Based on Individual Biomarkers
of Susceptibility: A Single-Institution Experience
Andrea Sartore-Bianchi1 & Alessio Amatu1 & Erica Bonazzina1 & Stefano Stabile1 &
Laura Giannetta1 & Giulio Cerea1 & Ilaria Schiavetto1 & Katia Bencardino1 &
Chiara Funaioli1 & Riccardo Ricotta1 & Tiziana Cipani1 & Michele Schirru1 &
Valentina Gambi1 & Laura Palmeri1 & Giulia Carlo-Stella1 & Francesca Rusconi1 &
Sara Di Bella1 & Giovanni Burrafato1 & Andrea Cassingena1 & Emanuele Valtorta1 &
Calogero Lauricella1 & Federica Pazzi1 & Alessandra Gambaro1 & Silvia Ghezzi1 &
Giovanna Marrapese1 & Emiliana Tarenzi1 & Silvio Veronese1 & Mauro Truini1 &
Angelo Vanzulli1,2 & Salvatore Siena1,2
Published online: 1 July 2017
# The Author(s) 2017. This article is an open access publication
Abstract
Background Patients with metastatic colorectal cancer
(mCRC) refractory to standard therapies have a poor progno-
sis. In this setting, recruitment into clinical trials is warranted,
and studies driven by selection according to individual tumor
molecular characteristics are expected to provide added value.
Objective We retrospectively analyzed data from patients
with mCRC refractory to or following failure of standard ther-
apies who were enrolled into phase I/II clinical studies at the
Niguarda Cancer Center based on the presence of a specific
molecular profile expected to represent the target of suscepti-
bility to the experimental drug(s).
Patients and Methods From June 2011 to May 2016, 2044
patients with mCRC underwent molecular screening. Eighty
patients (3.9%) were enrolled in ad hoc studies; the median
age was 60 years (range 36–86) and the median number of
previous treatment lines was five (range 2–8). Molecular char-
acteristics exploited within these studies wereMGMT promot-
er hypermethylation (48.7%), HER2 amplification (28.8%),
BRAFV600Emutation (20%), and novel gene fusions involving
ALK or NTRK (2.5%).
Results One patient (1%) had RECIST (Response Evaluation
Criteria In Solid Tumors) complete response (CR), 13 patients
(16.5%) experienced a partial response (PR), and 28 (35%) stable
disease (SD). Median progression-free survival (PFS) was
2.8 months (range 2.63–3.83), with 24% of patients displaying
PFS >5 months. Median growth modulation index (GMI) was
0.85 (range 0–15.61) and 32.5% of patients had GMI >1.33.
KRAS exon 2 mutations were found in 38.5% of patients, and
among the 78 patients with knownKRAS status, those with wild-
type tumors had longer PFS than those with mutated tumors
(3.80 [95% CI 2.80–5.03] vs. 2.13 months [95% CI 1.77–
2.87], respectively, p = 0.001). Median overall survival (OS)
was 7.83 months (range 7.17–9.33) for all patients, and patients
with KRAS wild-type tumors had longer OS than those with
mutated tumors (7.83 [95% CI 7.33–10.80] vs. 7.18 months
[95% CI 5.63–9.33], respectively, p = 0.06).
Conclusions This single-institution retrospective study indi-
cates that in a heavily pretreated population approximately
4% of mCRC tumors display a potential actionable molecular
context suitable for therapeutic intervention. Application of
molecular selection is challenging but improves clinical out-
come even in later lines of treatment.
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Key Points
Treatment of metastatic colorectal cancer (mCRC) 
patients driven by selection according to individual
tumor molecular characteristics is expected to provide 
enhanced clinical benefit.
In this single-institution retrospective analysis, 3.9% of
2044 patients were found to harbor biomarkers for ad hoc
phase I-II clinical studies, including MGMT promoter
hypermethylation, HER2 amplification, BRAFV600E
mutation, and gene fusions involving ALK or NTRK. 
14 patients had an objective response, and 28 stable disease. 
Median progression-free survival (PFS) was 2.8 months,
with 24% of patients displaying PFS >5 months.
1 Introduction
Colorectal cancer (CRC) remains a significant cause of mor-
bidity and mortality worldwide and many patients present
with metastatic disease despite large-scale screening programs
in various countries [1]. With the only exception of patients
presenting with oligometastatic lesions confined to the liver or
lung amenable to resection [2, 3], metastatic disease is consid-
ered incurable. In cases where treatment with curative intent is
excluded, patients are typically given a combination of cyto-
toxic chemotherapy, often in conjunction with a targeted
therapy.
Although advances in systemic therapy have been made,
the 5-year survival rate in this setting is still 12.5% [4], with
acquired resistance to therapy being the main reason for treat-
ment failure [5]. Indeed, resistance to targeted therapy, as
displayed by disease progression, is observed after a median
of 4 months on epidermal growth factor receptor (EGFR)
antagonists [45]. The discovery of RAS mutations in CRC as
a mechanism of innate resistance to these therapies has been
an important advance and has ameliorated their clinical use.
However, there is an unmet need for effective therapeutic
strategies after secondary resistance.
We have previously demonstrated that different molecular
alterations that drive resistance can occur simultaneously in
the same patient [7]. Identifying relevant molecular subtypes
within this heterogeneous disease and matching patients with
appropriate single agents or combinations of targeted thera-
pies at resistance is crucial to therapeutic progress [8].
Therefore, recruitment into precision oncology clinical trials
based on selection according to individual tumor molecular
characteristics is expected to provide added value.
We retrospectively collected data from patients with meta-
static CRC (mCRC) resistant to standard therapies treated at
the Niguarda Cancer Center (NCC) (Milan, Italy) in phase I/II
clinical studies based on the presence of specific tumor mo-
lecular profiles conferring susceptibility to experimental
drugs, and performed a pooled analysis for measuring results
according to main clinical and other molecular variables.
2 Methods
2.1 Patients
We retrospectively collected data from patients with mCRC
resistant to standard therapies treated at NCC between
June 2011 and May 2016 in phase I/II clinical studies, includ-
ing one phase I first-in-human study, based on the presence of
specific biomarkers that confer susceptibility to experimental
drugs (Table 1). These included tumor genetic alterations (i.e.,
gene mutations, amplifications, or fusions) or a certain genetic
context (i.e., methylation of specific genes). Consecutive eli-
gible patients were offered participation in clinical trials. All
patients gave written informed consent and the study and all
treatments were conducted in accordance with the guidelines
of the Institutional Review Board at Ospedale Niguarda.
The presence of the particular biomarker was investigated
according to specific study protocol criteria or retrieved by
medical history, where applicable. Further molecular charac-
terization of Kirsten rat sarcoma viral oncogene homolog
(KRAS) mutations, a well-known biomarker associated with
poor prognosis, was performed in all available samples of
patients included in the studies by the Pathology Department
of NCC as per standard of care. The registration of patients in
the database, pathology assessment, and additional mutation
analyses if needed were performed at NCC.
2.2 Treatment and Evaluation
Treatment was carried out according to the specific requisites
of treatment protocols and was continued until disease pro-
gression, unacceptable toxicity, or withdrawal of consent.
Assessments, including history, physical examination, and
laboratory evaluations, were performed as specified in each
protocol, typically before the initiation of therapy, and longi-
tudinally during the treatment cycles. Efficacy was assessed
from computed tomography scans and/or magnetic resonance
imaging at baseline before treatment initiation and then every
6–8 weeks depending on the study protocol. All radiographs
were evaluated by the Department of Radiology at NCC and
responses were categorized per RECIST (Response
Evaluation Criteria In Solid Tumors) 1.1 criteria and were
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reported as best response [13]. Progression-free survival of the
treatment(PFSn)was recorded for each individual patient as in
the case report form of the respective trial, whereas
progression-free survival achieved with the previous treat-
ment line received by the patient (PFSn–1) was calculated
based on available clinical documentation.
2.3 Statistical Analysis
Fisher’s exact test was used to assess the association
among categorical variables and the presence of the bio-
marker used for treatment selection. Progression-free sur-
vival (PFS) was defined as the time interval from the start
of therapy to the first observation of disease progression
or death, whichever occurred first. All tests were 2-sided,
and p < 0.05 was considered statistically significant.
Multivariate analysis was performed by Cox logistic re-
gression; the model as a whole was evaluated by likeli-
hood ratio test, whereas the significance of the single in-
dependent variables was evaluated by means of the Wald
test. Results of the multivariate analysis should be
interpreted with caution due to the small sample size
and sampling bias of our study.
PFS and overall survival (OS) for all patients were
computed using the Kaplan-Meier method and differ-
ences in PFS and OS were calculated with log-rank test
where applicable. The growth modulation index (GMI)
has been applied as previously described [14]. We con-
sider a GMI >1.33, i.e., an increase in the PFSn/PFSn–1
ratio of 30%, as clinically meaningful. All statistical
analyses were carried out using R software [15] and
graphics were generated with ggplot2 [16].
3 Results
From June 2011 to May 2016, 2044 patients with mCRC
were referred to NCC for molecular screening for the
inclusion into phase I/II trials encompassing the targeting
of actionable molecular alterations or molecular contexts
of susceptibility. In total, 80 patients (3.9%) were enrolled
into six ad hoc studies: one phase I/II and five phase II
trials.
The median age was 60 years (range 36–86) and the
median number of previous treatment lines was five
(range 2–8). The six studies included therapies based on
MGMT promoter hypermethylation (48.7%), HER2 ampli-
fication (28.8%), BRAFV600E mutation (20%), and gene
fusions involving ALK or TRKA (2.5%) (Table 1 and
Fig. 1). Among the 78 of 80 patients evaluable for
KRAS mutations, any KRAS (exon 2) mutation was found
in 30 (38.5%) of patients.
According to RECIST 1.1 criteria, one patient (1%)
had complete response (CR), 13 patients (16.5%) had par-
tial response (PR), and 28 (35%) had stable disease (SD),
accounting for a 52.5% disease control rate (DCR =
CR + PR + SD). The DCR was higher in patients with
KRAS wild-type tumors (66 vs. 38%, p = 0.02). The me-
dian PFS was 2.8 months (range 2.63–3.83) (Fig. 2a), and
24% of patients displayed a PFS >5 months. A multivar-
iate analysis of clinicopathological factors including age,
gender, performance status, carcinoembryonic antigen
(CEA) levels, and KRAS status showed that KRAS status
and age were significantly associated with PFS (p = 0.011
and 0.047, respectively), whereas CEA and age were sig-
nificantly associated with OS (p = 0.0063 and 0.0279,
respectively). Patients with KRAS wild-type tumors had
longer PFS than those with mutated tumors (3.80 [95%
CI 2.80–5.03] vs. 2.13 months [95% CI 1.77–2.87], re-
spectively) (p = 0.001) (Fig. 2b). Median OS was
7.83 months (range 7.17–9.33) (Fig. 3a), and patients with
KRAS wild-type tumors had longer OS than those with
mutated tumors (7.83 [95% CI 7.33–10.80] vs.
7.18 months [95% CI 5.63–9.33], respectively, p = 0.06)
(Fig. 3b). The median GMI was 0.85 (range 0–15.61) and
32.5% of patients had a GMI >1.33 (Fig. 4). The
Spearman Rho between PFSn and PFSn–1 was 0.10
(p = 0.372).
Table 1 Distribution of patients in clinical trials with actionable molecular alterations treated with matched targeted agents included in the pooled
analysis
Biomarker Study drug(s) EudraCT N° Patients (n)
MGMT promoter hypermethylation Temozolomide [9] 2012–003338-17 27
HER2 amplification Trastuzumab + lapatinib [10] 2012–002128-33 23
MGMT promoter hypermethylation Dacarbazine [11] 2011–002080-21 12
BRAF mutation MEK162 + LGX818 [NCT01543698] 2011–005875-17 9
BRAF mutation MEK162 + panitumumab [NCT01927341] 2013–001986-18 7
NTRK or ALK gene fusions Entrectinib [12] 2012–000148-88 2
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4 Discussion
In this single-institution retrospective analysis we found that
4.0% of mCRC patients refractory to standard therapies were
eligible for enrollment into phase I/II clinical trials based on
molecular target selection. These patients, who had experienced
a median number of five lines of previous treatments, achieved a
median PFS of 2.8 months (with approximately one-quarter of
patients displaying a PFS >5 months) and a median OS of
7.8 months. These data should be evaluated in the context of
advanced mCRC, where the median PFS with newer agents
has been less than 2 months [20], and rechallenge with standard
chemotherapy [18, 19] or further chemotherapy [17] showed
only poor efficacy and was burdened by adverse effects [21].
With regards to objective response rates (ORRs), 14 patients
(17.5%) had PR and 28 (35%) SD, accounting for a 52.5%
DCR. These data compare favorably with those achieved with
licensed third-line therapies such as the multikinase inhibitor
regorafenib (ORR = 1–4%) and the trifluridine–tipiracil combi-
nation TAS-102 (ORR = 2%), both of which are administered
without the selection of amolecular target, or salvage chemother-
apy with mitomycin-C or oxaliplatin rechallenge [17, 22, 23].
Following the seminal work by von Hoff et al. [14], several
reports investigating the use of molecularly targeted agents on
the basis of the identification ofmolecular alterations provided
conflicting results [43, 44]. Provocative findings from Janku
et al. highlighted that in phase I studies the lack of matching
between molecular alterations and targeted treatment provides
only limited clinical benefit in CRC and other solid tumors
[24]. Recently, the same authors reported findings of a pro-
spective, single-center ‘navigation’ study conducted in 500
patients with several different refractory cancers who
underwent comprehensive genomic profiling by sequencing
of 236 genes, offering proof-of-concept for the utility of this
approach in assigning therapy to patients with refractory ma-
lignancies, especially in those patients with multiple genomic
aberrations for whom combination therapies could be imple-
mented [25]. However, patients with CRC were only a small
proportion of this cohort and therefore definitive conclusions
could not be drawn for this histology. In mCRC, Dienstmann
et al. reported a series of 68 patients treated with targeted
agents in phase I trials based on molecular profiling, conclud-
ing that this approach did not confer a significant clinical
benefit on the basis of a comparison between the median time
to treatment failure n (TTFn) of 7.9 weeks and TTFn–1 of
16.3 weeks [26]. Similarly, in our present analysis of 80 pa-
tients, we observed that PFSn was inferior to PFSn–1 (12.0 vs.
15.6 weeks). However, there are substantial differences be-
tween these two cohorts. Our series included only 2.5% pa-
tients treated within a phase I study versus 100% of the pa-
tients included in the study by Dienstmann et al. [26], and
there are differences in the molecular alterations on which
the treatments are based (KRAS/BRAF/PIK3CA mutations,
PTEN and MET expression vs. HER2, BRAF, MGMT, and
gene fusions, respectively). Assessment of clinical benefit by
means of the ratio between PFS with the actual targeted ther-
apy and that achieved with the previous line of treatment,
referred to as the GMI, has also been proposed [14]. When
we applied this index to our cohort, we found that at least one-
third of patients benefited from the enrollment in clinical trials
with targeted agents matched to selected actionable molecular
alterations, making our results meaningful.
Among the molecular abnormalities selected in our cohort,
we included gene fusions involving the ALK andNTRK genes.
These alterations have only recently been recognized as tar-
gets occurring at low prevalence in CRC [27]. In particular, in
2014 we reported the characterization of the TPM3-NTRK1
gene rearrangement as a recurring, although rare, event in
CRC. The concomitant discovery of entrectinib (NMS-P626;
RXDX-101) as a novel highly potent and selective pan-Trk
inhibitor by the group of Ardini et al. [28] enhanced the inter-
est in this target, with further development across different
Fig. 1 RECIST (Response
Evaluation Criteria In Solid
Tumors) objective response rates
according to molecular targets in
the pooled patient population. PR
partial response, SD stable
disease, PD progressive disease,
NA not assessed
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histologies and currently ongoing phase II studies, including
in CRC [12, 27]. Interestingly enough, the two gene fusions
involvingNTRK and ALK described in the present cohort were
previously unreported [29, 30], highlighting the challenge of a
comprehensive molecular pathology that should not merely
include gene fusions together with mutations and amplifica-
tions but also elucidate the exact fusion partner and oncogenic
potential for treatment with specific inhibitors.
During the last decade, the assessment of KRAS and neu-
roblastoma RAS viral oncogene homolog (NRAS) gained in-
creasing importance for an optimal management of mCRC
[31]. Mutations in KRAS codons 12 or 13 (in exon 2) affect
approximately 40% of patients with metastatic CRC [32].
About an additional 5% of CRC patients display mutations
inKRAS exons 3 or 4, usually at codon 61 or 146, and another
5% of CRC patients have mutations in NRAS in exons 2, 3, or
4. Extended RAS status (KRAS and NRAS exons 2, 3, and 4
mutations) is the validated biomarker of response to anti-
EGFR antibodies [31]. RAS mutant mCRC exhibit a signifi-
cantly higher cumulative incidence of lung, bone, and brain
metastasis [33–35]. The prognostic role of RAS mutations is
controversial, but increasing evidence shows a negative effect
Fig. 2 Progression-free survival
a for all patients; and b according
to KRAS status
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in the adjuvant and metastatic setting [36–38]. In our cohort,
KRASmutations showed an overall negative prognostic value,
since patients harboring KRAS-mutated tumors had shorter
PFS and OS. Also, DCR was more frequent in patients with
KRAS wild-type tumors. However, it should be taken into
account that half of the selected phase I/II trials were designed
for patients with KRAS wild-type tumors (Cmek2110 and
Cmek2116 for BRAF-mutated tumors, HER2 Amplification
for Colo-rectaL Cancer Enhanced Stratification-HERACLES
for HER2 amplified tumors) and most of the KRAS-mutated
patients were treated in the two studies (DETECT and
TEMECT with dacarbazine and temozolomide, respectively)
that were not based on directly targeting an oncogenic driver
but rather exploiting a molecular context of susceptibility.
Limitations of our study include the small sample size and
potential sampling bias, the notion that the use of GMI as an
index of clinical benefit in CRC has been criticized as there is
a lack of correlation between PFSn and PFSn–1 that is the
Fig. 3 Overall survival a for all
patients; and b according toKRAS
status
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statistical assumption for applying this method [39, 40], and
that KRAS-limited instead of extended RAS analysis was per-
formed in our cohort.
In conclusion, our single-institution study indicates
that in a heavily pretreated mCRC population about
4% of tumors display a potential actionable molecular
context suitable for phase I/II trials with matched ther-
apeutics. Comprehensive molecular selection is chal-
lenging, encompassing inclusion of actionable alterations
occurring at low frequency in CRC such as HER2 am-
plification [10] and rare gene fusions involving the ALK
and NTRK genes [41], but enhances therapeutic options
to be exploited in the advanced setting. This knowledge,
coupled with recent advancements in the understanding
of acquired resistance mechanisms to targeted agents
through liquid biopsy [8, 42] is expanding opportunities
of precision oncology therapies for CRC.
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